Breast cancer is the most common type of cancer in women, accounting for around 10% of all occurrences. Most cancer patients die because of metastasis, which is now untreatable. Despite this, there are several ways that can be used to reduce the intensity of breast cancer symptoms. This emphasizes the need to start breast cancer treatment and diagnosis as soon as possible to prevent the disease from spreading. Mammography and ultrasounds are useful for screening many people, but they are ineffective at identifying and grading breast cancer. However, they are useful for detecting breast cancer. Doctors continue to do these kinds of procedures. Advanced biomarker development has the potential to transform several parts of medicine. Some of these characteristics include early illness detection, disease progression monitoring, and the development of treatment programs for specific tumors. Patients have a better quality of life and suffer less harm because of obtaining more effective therapies in moderation. As a result, lipidomic and metabolomic signatures are emerging as promising biomarkers for improving breast cancer detection and treatment. The development of lipidomics was driven by these objectives. The analytical power of mass spectrometry and the lightning-fast pace of technological progress have enabled lipidomics to make significant strides in recent years. By discussing onco-lipidomics and other important cellular metabolic networks, as well as drug-related issues in breast cancer, this review aims to provide readers with the knowledge they need to get a deeper understanding of metabolism.
Ray et al. (Tue,) studied this question.